

IMPLICITY SUCCEEDS ITS FIRST FUNDRAISING



The young start-up has successfully raised funds from private investors (rhythmologists, doctors) and institutional investors (Kima Ventures). The presence of actors from the medical environment and more conventional investors testifies to the excellent positioning of the company, which participates in technological changes in the field of cardiology.

« This first raise of 800,000 euros will expand the team of developers, recruit the first commercial and continue to develop our product. The strong component of doctors in the circle of investors confirms our strategic choices » details Arnaud Rosier, CEO of Implicity.

The strengthening of the Regulatory and Regulatory Affairs team in early September allows Implicity to continue developing the platform.

The company plans to recruit commercial profiles from November 1st.

About Implicity

Created in May 2016, Implicity offers an innovative platform for remote monitoring of connected cardiac prostheses (pacemakers, defibrillators). Created by cardiologists for cardiologists, this service allows remote management of alerts from connected devices from 5 global manufacturers (Medtronic, Abbott, Boston Scientific, Biotronik, Liva Nova) via a single harmonized platform.

A filtering of the received alerts makes it possible to guarantee a better support of the patients and a saving of time for the rhythmologists.

Implicity's goal is to simplify and optimize the remote monitoring of connected cardiac implants to improve the quality of care provided, in particular by the use of artificial intelligence methods that have required several years of development.

www.implicit.fr

Contact

Dr Arnaud Rosier, CEO Implicity

18 rue Notre Dame de Lorette

75009 Paris

arnaud.rosier@implicit.fr

+ 33 6 71 26 67 99